Recently approved antiviral pill ‘paxlovid’ has been dubbed a game-changer. Despite this, concerns persist about the accessibility of the pill and who should be getting it first. Bioethicist Kerry Bowman shares insight on the issue
- Canadian Pfizer partner sues Arbutus Biopharma over COVID-19 vaccine patent
- Pfizer forecasts higher COVID-19 vaccine, pill sales in 2022, but analysts expected more
- Nova Scotians aged 30 and older can now book Pfizer COVID-19 shots